Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Giant invasive prolactinomas.

F Y Murphy1, D L Vesely, R M Jordan

  • 1Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock.

The American Journal of Medicine
|November 1, 1987
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiac hormones eliminate some human squamous lung carcinomas in athymic mice.

European journal of clinical investigation·2010
Same author

Cardiac hormones activate ERK 1/2 kinases in human fibroblasts.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2008
Same author

Cardiac and kidney hormones cure up to 86% of human small-cell lung cancers in mice.

European journal of clinical investigation·2008
Same author

Sex, smell and vasculitis: Henoch-Schönlein purpura in Kallmann's syndrome.

The West Virginia medical journal·2008
Same author

Phosphatidylinositol 3-kinase/Akt signaling mediates interleukin-6 protection against p53-induced apoptosis in M1 myeloid leukemic cells.

Oncogene·2006
Same author

Urodilatin and four cardiac hormones decrease human renal carcinoma cell numbers.

European journal of clinical investigation·2006
Same journal

Mineralocorticoid Antagonists for Post-MI HFpEF: Plausible Biology Meets Low Residual Risk?

The American journal of medicine·2026
Same journal

GLP-1 Receptor Agonists and Age-related Macular Degeneration Risk in Diabetes or Non-diabetic Obesity: A Retrospective Cohort Study.

The American journal of medicine·2026
Same journal

Marijuana Use and Acute Myocardial Infarction: Mechanistic Insights, Clinical Implications, and Emerging Challenges.

The American journal of medicine·2026
Same journal

Cave Canem - Beware of the Dog.

The American journal of medicine·2026
Same journal

Risk Factors for 30-day Hospital Readmission After Hospital-at-Home Treatment of Acute Pyelonephritis.

The American journal of medicine·2026
Same journal

Mesenteric panniculitis.

The American journal of medicine·2026
See all related articles

Aggressive invasive prolactinomas require extensive treatment. Long-term, high-dose bromocriptine therapy, alongside surgery and radiation, can reduce these difficult-to-treat pituitary tumors.

Area of Science:

  • Endocrinology
  • Neurosurgery
  • Oncology

Background:

  • Prolactinomas are pituitary tumors that secrete prolactin.
  • Invasive prolactinomas can grow extensively, posing significant treatment challenges.

Observation:

  • Two extreme cases of invasive prolactinomas, followed for 9 and 10 years, exhibited aggressive growth patterns.
  • One tumor invaded auditory canals and skull base, while the other infiltrated sinuses.

Findings:

  • Neurosurgical debulking and radiation therapy showed limited initial success in reducing tumor size and prolactin levels.
  • Addition of bromocriptine after five years led to gradual tumor shrinkage and decreased prolactin levels.

Implications:

  • These cases highlight the need for prolonged and aggressive treatment strategies for invasive prolactinomas.

Related Experiment Videos

  • High-dose, long-term bromocriptine therapy may be essential for managing these complex pituitary tumors.